New York, Nov 20th, 2018 – Creative Biogene, a leading provider of genomics and proteomics products and service, recently announced the release of oncolytic virus products and related service which can offer professional support for oncolytic studies, thereby promoting the application for the treatment of tumors. The oncolytic program in Creative Biogene enhances its capabilities with a broad range of oncolytic virus engineering scope for initial early-stage clinical evaluation.
At present, oncolytic virus therapy is an innovative treatment and have enormous therapeutic potential as the oncolytic virus can selectively replicate in and lyse cancer cells, then spread with the tumor without causing damage to normal cells. In this stage, most tumors have already evolved, that is, they can avoid immune detection and destruction, even the cell apoptosis and inhibition of transformation. But the oncolytic virus can kill infected tumors in a number of different ways, ranging from direct virus-mediated cytotoxicity to various cytotoxic immune mechanisms.
However, due to the large size and immunogenicity of oncolytic viruses, they are limited by physical barriers and host immunity, but they can also cross-prime and amplify anti-tumor immunity as a cancer immunotherapy. In addition to the expected clinical approval of OVs as a single agent, scientists still expect to develop more complex solutions to achieve superior therapeutic results. Preclinical research provides a solid foundation for this claim, demonstrating many synergistic interactions that can overcome the various barriers that limit OV.
Creative Biogene has established a QVirusTM platform, which can help the oncolytic programs step into a preliminary early clinical assessment. Meanwhile, our professional scientists spent years of efforts in oncolytic virus research so that we can offer in-time technique and theory support for any issues in the development of the oncolytic program. The oncolytic viruses that are available in Creative Biogene include herpes simplex virus, adenovirus, measles virus, vaccinia virus, and thyroid inflammatory stomatitis virus.
‘We offer customized, reliable and high-quality oncolytic virus treatment development services ranging from viral engineering, cell analysis to animal testing.’ Said Wendy Wilson, the marketing director of Creative Biogene, ‘To date, we have established various types of oncolytic virus engineering systems to facilitate the development of oncolytic viruses in less time and lower budget. Moreover, GMP-compliant oncolytic virus production is also included in our services.’
Measles Virus (MeV) and Herpes Simplex Virus (HSV-1) is now available on Creative Biogene which can fully support your oncolytic studies.
About Creative Biogene
Founded in 2005, Creative Biogene provides scientists with innovative genomics and proteomics-based biological research reagent products to greatly enhance the development of the human condition through biotechnology. Creative Biogene is a well-recognized industry leader with more than 10-years experience that supports studies worldwide through the professional expert team.
Company Name: Creative Biogene
Contact Person: Wendy Wilson
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States